Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herb takes on transplant complication: Withaferin-A tested for Steroid-Resistant GVHD

NCT ID NCT07708987

Recruiting now Disease control Sponsor: Tata Memorial Centre Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a standardized extract from the ashwagandha plant, called Withaferin-A, can help people who develop graft-versus-host disease after a stem cell transplant and whose condition does not improve with steroids. The study enrolls 34 patients aged 12 and older with blood cancers who have received a donor stem cell transplant. Participants take the extract by mouth daily for at least 12 weeks, and researchers measure how many patients respond to treatment after 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
standardized Withaferin-A (root extract of Withania somnifera)
What this could lead to
If effective, this could offer a new treatment option for patients with steroid-resistant graft-versus-host disease, potentially reducing the need for strong immunosuppressants.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The treatment may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD - GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD - GRAFT-VERSUS-HOST DISEASE HEMATOLOGICAL MALIGNANCY STERIOD REFRACTORY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Advanced Centre for Treatment, Research and Education in Cancer

    RECRUITING

    Navi Mumbai, Maharashtra, 410210, India

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.